Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis
Purpose of Review Immune checkpoint inhibitors have reshaped the treatment of cancer, but they are characterized by peculiar toxicity consisting of immune-related adverse events that may potentially affect any organ or system. In this review, we summarize data on clinical presentation, diagnosis, pathogenesis, and management of the main immune-related cardiovascular toxicities of immune checkpoint inhibitors. Recent Findings The most relevant immune-related cardiovascular toxicity is myocarditis, but other non-negligible reported events include non-inflammatory heart failure, conduction abnormalities, pericardial disease, and vasculitis. More recently, growing evidence suggests a role for immune checkpoint inhibitors in accelerating atherosclerosis and promoting plaque inflammation, thus leading to myocardial infarction. Summary Immune checkpoint inhibitors are associated with several forms of cardiovascular toxicity; thus, an accurate cardiovascular baseline evaluation and periodical monitoring are required. Furthermore, the optimization of cardiovascular risk factors before, during, and after treatment may contribute to mitigating both short-term and long-term cardiovascular toxicity of these drugs..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current oncology reports - 25(2023), 7 vom: 05. Apr., Seite 743-751 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Inno, Alessandro [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Atherosclerosis |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11912-023-01411-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051846772 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051846772 | ||
| 003 | DE-627 | ||
| 005 | 20230610064727.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230610s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11912-023-01411-7 |2 doi | |
| 035 | |a (DE-627)SPR051846772 | ||
| 035 | |a (SPR)s11912-023-01411-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Inno, Alessandro |e verfasserin |0 (orcid)0000-0001-6331-6908 |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of Review Immune checkpoint inhibitors have reshaped the treatment of cancer, but they are characterized by peculiar toxicity consisting of immune-related adverse events that may potentially affect any organ or system. In this review, we summarize data on clinical presentation, diagnosis, pathogenesis, and management of the main immune-related cardiovascular toxicities of immune checkpoint inhibitors. Recent Findings The most relevant immune-related cardiovascular toxicity is myocarditis, but other non-negligible reported events include non-inflammatory heart failure, conduction abnormalities, pericardial disease, and vasculitis. More recently, growing evidence suggests a role for immune checkpoint inhibitors in accelerating atherosclerosis and promoting plaque inflammation, thus leading to myocardial infarction. Summary Immune checkpoint inhibitors are associated with several forms of cardiovascular toxicity; thus, an accurate cardiovascular baseline evaluation and periodical monitoring are required. Furthermore, the optimization of cardiovascular risk factors before, during, and after treatment may contribute to mitigating both short-term and long-term cardiovascular toxicity of these drugs. | ||
| 650 | 4 | |a Immunotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Myocarditis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pericardial disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Atherosclerosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Myocardial infarction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Conduction disease |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Tarantini, Luigi |4 aut | |
| 700 | 1 | |a Parrini, Iris |4 aut | |
| 700 | 1 | |a Spallarossa, Paolo |4 aut | |
| 700 | 1 | |a Maurea, Nicola |4 aut | |
| 700 | 1 | |a Bisceglia, Irma |4 aut | |
| 700 | 1 | |a Silvestris, Nicola |4 aut | |
| 700 | 1 | |a Russo, Antonio |4 aut | |
| 700 | 1 | |a Gori, Stefania |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology reports |d Philadelphia, Pa. : Current Science, Inc., 1999 |g 25(2023), 7 vom: 05. Apr., Seite 743-751 |w (DE-627)SPR022982957 |w (DE-600)2054295-1 |x 1534-6269 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:7 |g day:05 |g month:04 |g pages:743-751 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11912-023-01411-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 7 |b 05 |c 04 |h 743-751 | ||